U.S. market Open. Closes in 5 hours 19 minutes

FIXX | Homology Medicines, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for FIXX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak.

Valuation (21%)

Company Industry
P/E Ratio (TTM) -0.01 -23.59
PEG Ratio (TTM) 0.00 15.25
P/S Ratio (TTM) 1.70 49.66
P/B Ratio (TTM) 0.02 18.49
P/FCF Ratio (TTM) -0.04 -3.08
Price to 5YR AVG Earnings Ratio 0.00 -2.76
Price to 5YR AVG FCF Ratio -0.03 -8.68

Profitability (0%)

Company Industry
ROA (TTM) -54.54% -5.20%
ROE (TTM) -100.91% 18.76%
Net Profit Margin (TTM) -4,688.94% -1,547.69%
ROIC 5YR AVG -114.03% 15.82%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 34.51% -6,933.03% -8,816.27%
Revenue -63.97% 388.22% 202.03%
Net Income 35.49% -25.38% -4,692.60%
Cash Flow 12.46% -44.75% -24.50%

Health (47%)

Company Industry
Current Ratio (TTM) 4.19 6.18
Quick Ratio (TTM) 4.11 5.90
D/E Ratio (TTM) 0.19 -16.16
Interest Coverage (TTM) -58.59 -1.69
Piotroski F-Score 3 5
Altman Z-Score N/A 13.95
LTL to 5YR AVG FCF N/A 0.17
Shares Outstanding Growth 5YR AVG -13.04% 129.81%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙